October 12 reveals prostate cancer aggressiveness with PARP inhibitor therapeutic alternative

October 12 reveals prostate cancer aggressiveness with PARP inhibitor therapeutic alternative

It has been shown that survival of patients with these changes may improve with the use of these drugs, called PARP inhibitors. + read more

They found the molecular mechanism by which most mutations in the gene cause breast and ovarian cancer.

Decades after discoveries linking mutations in the BRCA1 gene with susceptibility to breast and ovarian cancer, the molecular mechanism by which most of these mutations lead to cancer in women has been identified. + read more

The prognosis of one of the most aggressive forms of prostate cancer is determined by other tumor changes.

One of the most aggressive forms of prostate cancer, caused by inherited mutations of the BRCA2 gene, fatally improves or worsens the prognosis, regardless of whether it is accompanied by certain changes that are not inherited but originate in the tumor. + read more

18% of male breast cancer patients have mutations in the inherited risk genes BRCA1 and BRCA2.

Patients with this genetic alteration have varying characteristics with a worse prognosis, with a higher prevalence of advanced de novo disease (with metastases at diagnosis) and progression-free survival (PFS) data that suggest a more aggressive disease course. . + read more

They identify cells that can lead to breast cancer

Some types of breast cancer usually appear at an early age and are clinically aggressive, so early detection is necessary. + read more

They are finding a new way to find possible biomarkers and identify subtypes of prostate cancer.

Prostate cancer has several subtypes that can be successfully treated with targeted therapy for each patient. + read more